Back to Search
Start Over
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years
- Source :
- Multiple Sclerosis and Related Disorders; April 2021, Vol. 49 Issue: 1
- Publication Year :
- 2021
-
Abstract
- •Across age groups, alemtuzumab efficacy was greater than SC IFNB-1a over 2 years.•Alemtuzumab maintained clinical and MRI efficacy over 8 years in all age groups.•Age-related increases in serious infections, malignancies, and deaths were observed.
Details
- Language :
- English
- ISSN :
- 22110348
- Volume :
- 49
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Multiple Sclerosis and Related Disorders
- Publication Type :
- Periodical
- Accession number :
- ejs54937370
- Full Text :
- https://doi.org/10.1016/j.msard.2020.102717